Ardelyx (ARDX) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Financial performance and growth

• Achieved $319 million in combined revenue from two products, with $158 million from IBSRELA and $161 million from XPHOZAH in the last year.

• IBSRELA sales grew nearly 100% year-over-year, and XPHOZAH saw strong growth in its first launch year.

• Ended the year with $250 million in cash, providing a strong financial foundation for future business development.

• Guidance for IBSRELA in 2025 is $240–$250 million, representing 52% annual growth.

• XPHOZAH is expected to generate up to $750 million in revenue from non-Medicare patients, focusing on 40% of the dialysis population.

Commercial strategy and execution

• Expanded sales force from 64 to 124, leading to over 30% quarter-over-quarter growth for IBSRELA in Q4.

• Broadened target healthcare providers to include high-prescribing GIs, APPs, and non-GIs, reaching 14,000 practitioners.

• Enhanced patient services through Ardelyx Assist, supporting prescription fulfillment and access.

• Field access manager team expansion in 2025 to improve pull-through and patient access.

• Focused on both top-of-funnel demand generation and bottom-of-funnel patient support.

Product innovation and market opportunity

• IBSRELA addresses unmet needs in IBS-C with a novel mechanism, offering rapid and lasting symptom relief.

• XPHOZAH is the first phosphate absorption inhibitor for dialysis patients in over 50 years, simplifying treatment and improving phosphorus management.

• XPHOZAH enables patients to reach serum phosphorus targets, potentially reducing morbidity and mortality.

• Patient assistance programs ensure access for Medicare patients affected by reimbursement changes.

• Dedicated efforts underway for international expansion and pipeline development.